Kyverna Therapeutics (KYTX) Projected to Post Quarterly Earnings on Tuesday

Kyverna Therapeutics (NASDAQ:KYTX) is projected to issue its quarterly earnings data before the market opens on Tuesday, March 25th. Analysts expect the company to announce earnings of ($0.84) per share for the quarter.

Kyverna Therapeutics Stock Up 1.6 %

NASDAQ KYTX opened at $2.54 on Tuesday. The company has a fifty day moving average of $3.05 and a two-hundred day moving average of $4.45. Kyverna Therapeutics has a 52 week low of $2.38 and a 52 week high of $29.96.

Analysts Set New Price Targets

Separately, HC Wainwright dropped their price objective on shares of Kyverna Therapeutics from $7.00 to $6.00 and set a “neutral” rating for the company in a research note on Wednesday, November 20th. One investment analyst has rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $18.40.

Institutional Trading of Kyverna Therapeutics

An institutional investor recently raised its position in Kyverna Therapeutics stock. Bank of America Corp DE grew its stake in shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX) by 41.6% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 21,788 shares of the company’s stock after purchasing an additional 6,400 shares during the quarter. Bank of America Corp DE owned approximately 0.05% of Kyverna Therapeutics worth $81,000 at the end of the most recent quarter. 18.08% of the stock is currently owned by institutional investors.

Kyverna Therapeutics Company Profile

Kyverna Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.